TNF Receptor

Tumor Necrosis Factor Receptor; TNFR

TNF Receptor

TNF Receptor Isoform Specific Products:

TNF Receptor Related Products (1074)
Recombinant Proteins (284)
Antibodies (23)
TNF Receptor Signaling Pathway
TNF Receptor Isoform Comparison

By Effects:	Inhibitors (765)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-118828B

12-Oxo phytodienoic acid (≥90%)	Inhibitor
12-Oxo phytodienoic acid (≥90%) (12-OPDA (≥90%)) is a plant lipid-derived anti-inflammatory compound. 12-Oxo phytodienoic acid (≥90%) induces the expression of SOCS-1 and inhibits LPS (HY-D1056)-induced activation of the NF-κB and p38 MAPK signaling pathways. 12-Oxo phytodienoic acid (≥90%) inhibits LPS-induced expression of IL-6 and TNF-α, and reduces LPS-induced NO production by decreasing iNOS levels. 12-Oxo phytodienoic acid (≥90%) induces activation of the Nrf2 signaling cascade. 12-Oxo phytodienoic acid (≥90%) can be used for the research of neurodegenerative diseases.

HY-101481

Flurbiprofen axetil	Inhibitor	99.34%
Flurbiprofen axetil is a non-selective COX inhibitor and a nonsteroidal anti-inflammatory agent with anti-inflammatory and analgesic effects. Flurbiprofen axetil inhibits basal-like breast cancer metastasis by inhibiting the MEK/ERK signaling pathway. Flurbiprofen axetil can promote neuroprotection after focal cerebral ischemia in rats by partially activating PPAR-γ. Flurbiprofen axetil alleviates cerebral ischemia/reperfusion injury by reducing inflammation in a transient global cerebral ischemia/reperfusion rat model. Flurbiprofen axetil can alleviate inflammatory responses and cognitive function in a mild cognitive impairment (MCI) SD rat model through the AMPKα/NF-κB signaling pathway.

HY-160178

Glucocorticoid receptor agonist-3 Ala-Ala-Mal	Inhibitor	99.72%
Glucocorticoid receptor agonist-3 Ala-Ala-Mal (Compound Preparation 8) is an anti-human TNFα antibody-glucocorticoid receptor agonist (GC) conjugate. Glucocorticoid receptor agonist-3 Ala-Ala-Mal can be used in the study of autoimmune and inflammatory diseases.

HY-156817

TNIK-IN-6	Inhibitor	98.28%
TNIK-IN-6 (Compound 9) is an inhibitor of Traf2 and Nck-interacting kinase (TNIK) and , with IC₅₀ of 0.93 μM, that plays important roles in neurological and psychiatric disorders.

HY-N12188

Stigmasta-3,5-dien-7-one	Inhibitor	99.84%
Stigmasta-3,5-dien-7-one is a steroid compound that can be isolated from Harrisonia abyssinica. Stigmasta-3,5-dien-7-one blocks the NF-κB signaling pathway via down-regulation of phospho-p38 mitogen-activated protein kinase and phosphorylation and degradation of inhibitor of NF-κB α. Stigmasta-3,5-dien-7-one reduces LPS (HY-D1056)-induced nitric oxide, PGE₂, and pro-inflammatory cytokine levels in macrophages. Stigmasta-3,5-dien-7-one can be used for inflammation diseases.

HY-172590

LZ-07	Inhibitor	98.27%
LZ-07 is a IRAK4 PROTAC degrader (DC₅₀ = 1.14 nM). LZ-07 leads to marked suppression of cytokines including IL-6, IL-1β, TNF-α, and IL-10 upon degradation of IRAK4. LZ-07 can be studied in research for autoimmune diseases (Pink: IRAK4 ligand (HY-172591); Blue: CRBN ligand (HY-34590); Black: linker (HY-B0149); CRBN ligand + linker: HY-172593).

HY-P991570

Zaptuzumab	Inhibitor	99.0%
Zaptuzumab (AD5-10) is a DR5-specific humanized monoclonal antibody that selectively binds to DR5 with high affinity. Zaptuzumab specifically induces cancer cell death by both caspase-apoptosis and autophagic cell death (ACD). Zaptuzumab activates both ADCC and CDC. Zaptuzumab induces ROS generation and GSH level reduction. Zaptuzumab shows a significant suppression of the tumor growth and good safety in various xenografts mice tumor models.

HY-111326

Naphazoline	Inhibitor	99.74%
Naphazoline (Naphthazoline) is a potent α-adrenergic receptor agonist. Naphazoline reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF. Naphazoline can be used for non-bacterial conjunctivitis research.

HY-133807A

(Rac)-Benpyrine	Inhibitor	99.30%
(Rac)-Benpyrine, a racemate of Benpyrine, is a potent and orally active TNF-α inhibitor. (Rac)-Benpyrine has the potential for TNF-α mediated inflammatory and autoimmune disease research.

HY-P99821

Ravagalimab	Inhibitor	99.31%
Ravagalimab (ABBV-323) is a CD40 antagonist (EC₅₀: 3.7 nM). Ravagalimab can be used for research of Crohn's disease.

HY-P99057A

Varlilumab (anti-CD27)	Inhibitor	99.68%
Varlilumab (CDX-1127) (anti-CD27) is an agonist anti-CD27 monoclonal antibody. Varlilumab (anti-CD27) can promote T cell expansion and activate the immune response. Varlilumab (anti-CD27) has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors.

HY-P99321

Teneliximab	Inhibitor	≥99.0%
Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion.

HY-N8884

Coelonin	Inhibitor	98.0%
Coelonin is a dihydrophenanthrene with anti-inflammation activity. Coelonin inhibits LPS-induced PTEN phosphorylation. Coelonin inhibits NF-κB activation and p27Kip1 degradation by regulating the PI3K/AKT pathway negatively. Coelonin can inhibit IκBα phosphorylation and degradation and increases the expression of IκBα protein.

HY-100573S

Necrosulfonamide-d₄	Inhibitor	99.65%
Necrosulfonamide-d₄ is the deuterium labeled Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.

HY-145726

ISIS 104838	Inhibitor
ISIS 104838 is an antisense oligonucleotide targeting TNF-α. ISIS 104838 specifically binds to human TNF-α mRNA via Watson-Crick base pairing to form a DNA:RNA hybrid duplex, thereby recruiting the ubiquitously expressed intracellular enzyme RNase H to degrade the target mRNA and inhibit TNF-α protein synthesis at the transcriptional level. ISIS 104838 induces moderate, self-limiting thrombocytopenia in cynomolgus monkeys. ISIS 104838 can be used for the study of inflammatory diseases.

HY-101170

BU224 hydrochloride	Inhibitor
BU224 hydrochloride is a selective and high affinity imidazoline I₂ receptor ligand, with a K_i of 2.1 nM. BU224 hydrochloride is sometimes used as an I₂ receptor antagonist. BU224 hydrochloride exerts neuroprotective effects, with anti-inflammatory and anti-apoptotic properties. BU224 hydrochloride improves memory in 5XFAD mice, enlarging dendritic spines and reducing Aβ-induced changes in NMDARs. BU224 hydrochloride can be used for Alzheimer's disease research.

HY-B0026

Ceftiofur hydrochloride	Inhibitor	98.43%
Ceftiofur hydrochloride is a cell wall synthesis inhibitor that targets bacterial penicillin-binding proteins (PBPs) and has anti-inflammatory effects in endotoxemia. Ceftiofur hydrochloride exerts bactericidal effects by inhibiting the synthesis of bacterial cell wall peptidoglycan, leading to bacterial cell lysis. Ceftiofur hydrochloride also inhibits the activation of NF-κB and MAPKs, thereby reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6.

HY-P99825

Relfovetmab	Inhibitor	99.88%
Relfovetmab is an anti-NGF monoclonal antibody (mAb).

HY-P990919

Gimistotug	Inhibitor	98.59%
HY-P990919 is an TNFRSF4-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).

HY-N8435

Desoxo-narchinol A	Inhibitor	98.0%
Desoxo-narchinol A is an orally active and potent anti-inflammatory agent. Desoxo-narchinol A can be isolated from the roots and rhizomes of Nardostachys jatamansi. Desoxo-narchinol A can be used for septic shock and inflammatory diseases research.

TNF RIPK1 TRADD TRAF2/5 cIAP1/2 TNFR1 LUBAC TAB2 TAB3 TAK1 IKKβ NEMO IKKα RIPK1 CYLD RIPK1 RIPK1 TRADD FADD FADD Pro-caspase 8 Pro-caspase 8 Pro-caspase 8 Pro-caspase 8 Pro-caspase 8 Pro-caspase 8 Pro-caspase 8 Pro-caspase 8 Pro-caspase 8 Active
Caspase 8 Caspase 3/7 RIPK1 or
RIPK3 RIPK1 RIPK3 Apoptosis FADD RIPK1 RIPK3 FADD FLIP_L FLIP_L RIPK1 or
RIPK3 FLIP_L or FLIP_S FADD FADD RIPK1 RIPK3 RIPK3 RIPK3 MLKL MLKL MLKL AP1 TRAF1/2 cIAP1/2 MKK3 MKK1/7 p38 JNK CYLD IκB p50 p65 IκB NF-κB FLIP Bcl-X_L TNF TNFR2

Download TNF Receptor Signaling Pathway Map.

Following the binding of TNF to TNF receptors, TNFR1 binds to TRADD, which recruits RIPK1, TRAF2/5 and cIAP1/2 to form TNFR1 signaling complex I; TNFR2 binds to TRAF1/2 directly to recruit cIAP1/2. Both cIAP1 and cIAP2 are E3 ubiquitin ligases that add K63 linked polyubiquitin chains to RIPK1 and other components of the signaling complex. The ubiquitin ligase activity of the cIAPs is needed to recruit the LUBAC, which adds M1 linked linear polyubiquitin chains to RIPK1. K63 polyubiquitylated RIPK1 recruits TAB2, TAB3 and TAK1, which activate signaling mediated by JNK and p38, as well as the IκB kinase complex. The IKK complex then activates NF-κB signaling, which leads to the transcription of anti-apoptotic factors-such as FLIP and Bcl-XL-that promote cell survival.

The formation of TNFR1 complex IIa and complex IIb depends on non-ubiquitylated RIPK1. For the formation of complex IIa, ubiquitylated RIPK1 in complex I is deubiquitylated by CYLD. This deubiquitylated RIPK1 dissociates from the membrane-bound complex and moves into the cytosol, where it interacts with TRADD, FADD, Pro-caspase 8 and FLIPL to form complex IIa. By contrast, complex IIb is formed when the RIPK1 in complex I is not ubiquitylated owing to conditions that have resulted in the depletion of cIAPs, which normally ubiquitylate RIPK1. This non-ubiquitylated RIPK1 dissociates from complex I, moves into the cytosol, and assembles with FADD, Pro-caspase 8, FLIPL and RIPK3 (but not TRADD) to form complex IIb. For either complex IIa or complex IIb to prevent necroptosis, both RIPK1 and RIPK3 must be inactivated by the cleavage activity of the Pro-caspase 8-FLIPL heterodimer or fully activated caspase 8. The Pro-caspase 8 homodimer generates active Caspase 8, which is released from complex IIa and complex IIb. This active Caspase 8 then carries out cleavage reactions to activate downstream executioner caspases and thus induce classical apoptosis.

Formation of the complex IIc (necrosome) is initiated either by RIPK1 deubiquitylation mediated by CYLD or by RIPK1 non-ubiquitylation due to depletion of cIAPs, similar to complex IIa and complex IIb formation. RIPK1 recruits numerous RIPK3 molecules. They come together to form amyloid microfilaments called necrosomes. Activated RIPK3 phosphorylates and recruits MLKL, eventually leading to the formation of a supramolecular protein complex at the plasma membrane and necroptosis ^[1][2].

Reference:
[1]. Brenner D, et al. Regulation of tumour necrosis factor signalling: live or let die.Nat Rev Immunol. 2015 Jun;15(6):362-74.
[2]. Conrad M, et al. Regulated necrosis: disease relevance and therapeutic opportunities.Nat Rev Drug Discov. 2016 May;15(5):348-66.

Name
Email *

	Sorry, but the email address you supplied was invalid.

TNF Receptor

TNF Receptor

TNF Receptor Isoform Specific Products:

TNF Receptor Isoform Specific Products:

TNF Receptor Related Products (1074)

Recombinant Proteins (284)

Antibodies (23)

TNF Receptor Signaling Pathway

TNF Receptor Isoform Comparison

TNF Receptor Related Products (1074):